Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

N-Ethylmaleimide-Sensitive Factor Regulates β2 Adrenoceptor Trafficking and Signaling in Cardiomyocytes

Yongyu Wang, Benjamin Lauffer, Mark Von Zastrow, Brian K. Kobilka and Yang Xiang
Molecular Pharmacology August 2007, 72 (2) 429-439; DOI: https://doi.org/10.1124/mol.107.037747
Yongyu Wang
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois (Y.W., Y.X.); Program in Pharmaceutical Sciences and Pharmacogenomics and Department of Pharmaceutical Chemistry (B.L.), Department of Psychiatry and Department of Cellular and Molecular Pharmacology (M.V.Z.), University of California at San Francisco, San Francisco, California; and Department of Molecular and Cellular Physiology, Stanford Medical Center, Palo Alto, California (B.K.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Lauffer
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois (Y.W., Y.X.); Program in Pharmaceutical Sciences and Pharmacogenomics and Department of Pharmaceutical Chemistry (B.L.), Department of Psychiatry and Department of Cellular and Molecular Pharmacology (M.V.Z.), University of California at San Francisco, San Francisco, California; and Department of Molecular and Cellular Physiology, Stanford Medical Center, Palo Alto, California (B.K.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Von Zastrow
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois (Y.W., Y.X.); Program in Pharmaceutical Sciences and Pharmacogenomics and Department of Pharmaceutical Chemistry (B.L.), Department of Psychiatry and Department of Cellular and Molecular Pharmacology (M.V.Z.), University of California at San Francisco, San Francisco, California; and Department of Molecular and Cellular Physiology, Stanford Medical Center, Palo Alto, California (B.K.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian K. Kobilka
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois (Y.W., Y.X.); Program in Pharmaceutical Sciences and Pharmacogenomics and Department of Pharmaceutical Chemistry (B.L.), Department of Psychiatry and Department of Cellular and Molecular Pharmacology (M.V.Z.), University of California at San Francisco, San Francisco, California; and Department of Molecular and Cellular Physiology, Stanford Medical Center, Palo Alto, California (B.K.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Xiang
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois (Y.W., Y.X.); Program in Pharmaceutical Sciences and Pharmacogenomics and Department of Pharmaceutical Chemistry (B.L.), Department of Psychiatry and Department of Cellular and Molecular Pharmacology (M.V.Z.), University of California at San Francisco, San Francisco, California; and Department of Molecular and Cellular Physiology, Stanford Medical Center, Palo Alto, California (B.K.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recycling of G protein-coupled receptors determines the functional resensitization of receptors and is implicated in switching β2 adrenoceptor (β2AR) G protein specificity in cardiomyocytes. The human β2AR carboxyl end binds to the N-ethylmaleimide-sensitive factor (NSF), an ATPase integral to membrane trafficking machinery. It is interesting that the human β2AR (hβ2AR) carboxyl end pulled down NSF from mouse heart lysates, whereas the murine one did not. Despite this difference, both β2ARs exhibited substantial agonist-induced internalization, recycling, and Gi coupling in cardiomyocytes. The hβ2AR, however, displayed faster rates of agonist-induced internalization and recycling compared with the murine β2AR (mβ2AR) and a more profound Gi component in its contraction response. Replacing the mβ2AR proline (-1) with a leucine generated a gain-of-function mutation, mβ2AR-P417L, with a rescued ability to bind NSF, faster internalization and recycling than the mβ2AR, and a significant enhancement in Gi signaling, which mimics the hβ2AR. Selective disruption of the mβ2AR-P417L binding to NSF inhibited the receptor coupling to Gi. Mean-while, inhibiting NSF with N-ethylmaleimide blocked the mβ2AR recycling after agonist-induced endocytosis. Expressing the NSF-E329Q mutant lacking ATPase activity inhibited the mβ2AR coupling to Gi in cardiomyocytes. Our results revealed a dual regulation on hβ2AR trafficking and signaling by NSF through direct binding to cargo receptor and its ATPase activity and uncovered an unprecedented role for the receptor binding to NSF in regulating G protein specificity that has diverged between mouse and human β2ARs.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 72 (2)
Molecular Pharmacology
Vol. 72, Issue 2
1 Aug 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
N-Ethylmaleimide-Sensitive Factor Regulates β2 Adrenoceptor Trafficking and Signaling in Cardiomyocytes
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

N-Ethylmaleimide-Sensitive Factor Regulates β2 Adrenoceptor Trafficking and Signaling in Cardiomyocytes

Yongyu Wang, Benjamin Lauffer, Mark Von Zastrow, Brian K. Kobilka and Yang Xiang
Molecular Pharmacology August 1, 2007, 72 (2) 429-439; DOI: https://doi.org/10.1124/mol.107.037747

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

N-Ethylmaleimide-Sensitive Factor Regulates β2 Adrenoceptor Trafficking and Signaling in Cardiomyocytes

Yongyu Wang, Benjamin Lauffer, Mark Von Zastrow, Brian K. Kobilka and Yang Xiang
Molecular Pharmacology August 1, 2007, 72 (2) 429-439; DOI: https://doi.org/10.1124/mol.107.037747
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics